Propanc Biopharma, Inc. (PPCB) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-1 for Q3 FY2026, filed Jul 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PPCB SEC filings page.
This page shows Propanc Biopharma, Inc. (PPCB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Propanc Biopharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Propanc Biopharma, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 3 leverage/liquidity signals pass.
Propanc Biopharma, Inc. reported a net loss of $58.9M while operations used $405K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Propanc Biopharma, Inc. reported an operating loss of $57.3M against $564K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Propanc Biopharma, Inc.'s EBITDA was -$6.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 88.0% from the same quarter a year earlier. Against the prior quarter it is down 75.1%.
Propanc Biopharma, Inc. reported -$6.4M in net income in Q3 2026. This represents an increase of 88.2% from the same quarter a year earlier. Against the prior quarter it is down 105.7%.
Not reported for Q3 2026.
Cash & Balance Sheet
Propanc Biopharma, Inc. recorded an outflow of $1.1M in free cash flow in Q3 2026, representing a cash shortfall after capex. Against the prior quarter it is down 14.1%.
Propanc Biopharma, Inc. held $444K in cash against $55K in long-term debt as of Q3 2026, with $3.5M of liabilities due within a year.
Not reported for Q3 2026.
Margins & Returns
Propanc Biopharma, Inc.'s ROE was -64.7% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 234.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 35.1 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Propanc Biopharma, Inc. invested $170K in research and development in Q3 2026. This represents an increase of 213.6% from the same quarter a year earlier. Against the prior quarter it is up 750.0%.
Propanc Biopharma, Inc. invested $154 in capex in Q3 2026, funding long-term assets and infrastructure. Against the prior quarter it is down 93.2%.
Not reported for Q3 2026.
PPCB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 | Q4'24S-1 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $170K+213.6% | $20K-63.3% | $60K-2.5% | N/A | $54K-17.3% | $54K-52.3% | $62K+280.0% | N/A |
| SG&A Expenses | $6.2M-88.3% | $3.6M+2262.2% | $4.6M+1983.1% | N/A | $53.1M | $154K-51.7% | $221K-43.9% | N/A |
| Operating Income | -$6.4M+88.0% | -$3.7M-1612.8% | -$4.7M-1507.2% | N/A | -$53.1M | -$213K+51.3% | -$291K+30.3% | N/A |
| EBITDA | -$6.4M+88.0% | -$3.7M | -$4.7M | N/A | -$53.1M | N/A | N/A | N/A |
| Interest Expense | $38K-63.2% | $59K-50.4% | $306K+254.5% | N/A | $104K-21.9% | $119K-55.0% | $86K-51.6% | N/A |
| Net Income | -$6.4M+88.2% | -$3.1M | -$4.8M | N/A | -$54.1M | N/A | N/A | N/A |
| EPS (Basic) | -$7.09+97.7% | -$0.30+99.1% | -$0.39+98.9% | $594.27-65.9% | -$312.46+42.8% | -$32.23+97.9% | -$35.97-89825.0% | $1743.88+96982.2% |
| EPS (Diluted) | -$7.09 | -$0.30 | -$0.39 | $594.27 | -$312.46 | -$32.23 | -$35.97 | $1743.88 |
| Diluted Shares (Avg) | 897,099 | 13M | 12M | N/A | 173,040 | 13,347 | 9,849 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
PPCB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 | Q4'24S-1 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.3M-36.4% | $15.1M+19142.3% | $18.0M+28144.1% | $19.6M+27028.9% | $22.5M+60235.2% | $79K-67.5% | $64K-64.7% | $72K+20.0% |
| Current Assets | $8.2M-15.5% | $7.7M+42754.3% | $8.8M+40596.0% | $8.4M+32732.1% | $9.7M+75637.5% | $18K-91.5% | $22K-85.2% | $25K+33.6% |
| Cash & Equivalents | $444K+774.1% | $561K+3735.4% | $603K+6403.4% | $12K-42.7% | $51K+715.8% | $15K-79.6% | $9K+39.9% | $21K+109.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.5M-21.0% | $3.7M-13.6% | $3.6M-13.4% | $5.7M+48.7% | $4.4M+18.7% | $4.2M+11.3% | $4.2M+31.6% | $3.9M+21.2% |
| Current Liabilities | $3.5M-19.9% | $3.6M-12.8% | $3.6M-12.9% | $5.6M+47.1% | $4.3M+17.7% | $4.2M+10.4% | $4.1M+30.9% | $3.8M+20.1% |
| Non-Current Liabilities | $30K-67.8% | $35K-57.2% | $42K-40.3% | $147K+151.3% | $94K+92.2% | $82K+90.3% | $70K+93.0% | $59K+204.2% |
| Long-Term Debt | $55K-87.5% | $55K-86.6% | $107K-72.0% | $538K+34.7% | $439K-24.8% | $410K-40.4% | $382K-3.9% | $399K+2.2% |
| Total Equity | $9.8M-45.7% | $10.5M+351.3% | $14.4M+449.6% | $13.9M+468.0% | $18.1M+589.0% | -$4.2M-16.7% | -$4.1M-37.4% | -$3.8M-21.2% |
| Retained Earnings | -$140.8M-15.9% | -$134.5M-99.3% | -$130.5M-94.6% | -$125.6M-88.3% | -$121.6M-83.2% | -$67.5M-2.6% | -$67.1M-2.9% | -$66.7M-3.1% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
PPCB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 | Q4'24S-1 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.1M-1087.6% | -$999K-5434.7% | -$1.9M-723.3% | -$92K+64.5% | -$96K+6.4% | $19K+107.8% | -$236K+29.4% | -$260K-46.1% |
| Depreciation & Amortization | $316 | $229 | $125 | N/A | $0-100.0% | N/A | N/A | $0-100.0% |
| Stock-Based Compensation | $5.4M-89.9% | $1.8M | $3.0M | N/A | $52.8M | N/A | N/A | N/A |
| Capital Expenditures | $154 | $2K | $2K | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$1.1M | -$1.0M | -$1.9M | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$154 | -$2K | -$2K | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $982K+565.6% | $965K+1660.6% | $2.5M+1071.4% | $73K-71.0% | $147K+121.3% | $55K-80.0% | $216K-38.4% | $251K+151.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PPCB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-1 | Q2'26S-1 | Q1'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q1'25S-1 | Q4'24S-1 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -64.7%+234.1pp | -29.6% | -33.7% | N/A | -298.8% | N/A | N/A | N/A |
| Return on Assets | -44.4%+195.6pp | -20.5% | -26.9% | N/A | -240.0% | N/A | N/A | N/A |
| Current Ratio | 2.37+0.1x | 2.13+2.1x | 2.45+2.4x | 1.50+1.5x | 2.24+2.2x | 0.00-0.1x | 0.010.0x | 0.010.0x |
| Debt-to-Equity | 0.010.0x | 0.01 | 0.01 | 0.04 | 0.02 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Propanc Biopharma, Inc. PPCB | FY2025 | N/A | -$58.9M | N/A | $2.1M | — |
| Akari Therapeutics Plc AKTX | FY2025 | N/A | -$17.3M | N/A | $21.2M | — |
| Lixte Biotechnology Hldgs Inc LIXT | FY2025 | N/A | -$6.1M | N/A | $125.4M | — |
| Allarity ALLR | FY2025 | $320K | -$11.2M | N/A | $19.9M | — |
| BOUNDLESS BIO INC BOLD | FY2025 | N/A | -$58.2M | N/A | $64.6M | — |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $67.4M | — |
Where Propanc Biopharma, Inc. Ranks
Frequently Asked Questions
Is Propanc Biopharma, Inc. profitable?
No, Propanc Biopharma, Inc. (PPCB) reported a net income of -$58.9M in fiscal year 2025.
How much debt does Propanc Biopharma, Inc. have?
As of fiscal year 2025, Propanc Biopharma, Inc. (PPCB) had $12K in cash and equivalents against $538K in long-term debt.
What is Propanc Biopharma, Inc.'s return on equity (ROE)?
Propanc Biopharma, Inc. (PPCB) has a return on equity of -423.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Propanc Biopharma, Inc.'s operating cash flow?
Propanc Biopharma, Inc. (PPCB) recorded an outflow of $405K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Propanc Biopharma, Inc.'s total assets?
Propanc Biopharma, Inc. (PPCB) had $19.6M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Propanc Biopharma, Inc. spend on research and development?
Propanc Biopharma, Inc. (PPCB) invested $224K in research and development during fiscal year 2025.
What is Propanc Biopharma, Inc.'s current ratio?
Propanc Biopharma, Inc. (PPCB) had a current ratio of 1.50 as of fiscal year 2025, which is considered adequate.
What is Propanc Biopharma, Inc.'s debt-to-equity ratio?
Propanc Biopharma, Inc. (PPCB) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Propanc Biopharma, Inc.'s return on assets (ROA)?
Propanc Biopharma, Inc. (PPCB) had a return on assets of -300.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Propanc Biopharma, Inc.'s P/E ratio?
Propanc Biopharma, Inc. (PPCB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.1M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Propanc Biopharma, Inc.'s price-to-sales ratio?
Propanc Biopharma, Inc. (PPCB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.1M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Propanc Biopharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Propanc Biopharma, Inc. (PPCB) held $12K in cash, cash equivalents and investments, and reported an operating cash outflow of $405K over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Propanc Biopharma, Inc.'s Piotroski F-Score?
Propanc Biopharma, Inc. (PPCB) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Propanc Biopharma, Inc.'s earnings high quality?
Propanc Biopharma, Inc. (PPCB) reported a net loss of $58.9M while operations used $405K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Propanc Biopharma, Inc. cover its interest payments?
Propanc Biopharma, Inc. (PPCB) reported an operating loss of $57.3M against $564K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.